Log in to your Inderes Free account to see all free content on this page.
Sprint Bioscience
2.50 SEK
-3.85 %
Less than 1K followers
SPRINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-3.85 %
+26.58 %
+70.07 %
+70.07 %
+323.73 %
+260.59 %
+345.99 %
-45.36 %
-78.70 %
Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.
Read moreMarket cap
263.79M SEK
Turnover
861.12K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13.5.
2026
Interim report Q1'26
13.5.
2026
General meeting '26
26.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Positive results expand the NNMT program into Chronic Kidney Disease
Sprint Bioscience publishes new research findings that strengthen the potential of DCPS inhibitors in AML
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio